Eric Leblanc

Medicine · Health Sciences

22h-index1.7kcitations72works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Prostate Cancer Treatment and Research(54), Estrogen and related hormone effects(40), Radiopharmaceutical Chemistry and Applications(15), Hormonal and reproductive studies(13), Ubiquitin and proteasome pathways(10)

Publications72 total

A0597 – Unraveling the role of FBXW7 in muscle-invasive Bladder Cancer: Targeting MYC for therapeutic advantage
European Urology·2025
21 FBXW7 loss-of-function is associated with worse overall survival and leads to the accumulation of MYC in muscle-invasive bladder cancer
European Urology Open Science·2025Open Access
Novel Inhibitors of androgen receptor's DNA binding domain identified using an ultra‐large virtual screening
Molecular Informatics·2023· 7 citedOpen Access
Supplementary Figure 4 from Characterization of a New Class of Androgen Receptor Antagonists with Potential Therapeutic Application in Advanced Prostate Cancer
2023Open Access
Table S1 and Figure S1-S4 from Bypassing Drug Resistance Mechanisms of Prostate Cancer with Small Molecules that Target Androgen Receptor–Chromatin Interactions
2023Open Access
Supplementary Figure 1 from Characterization of a New Class of Androgen Receptor Antagonists with Potential Therapeutic Application in Advanced Prostate Cancer
2023Open Access
Supplementary Materials and Methods from Characterization of a New Class of Androgen Receptor Antagonists with Potential Therapeutic Application in Advanced Prostate Cancer
2023Open Access
Data from Bypassing Drug Resistance Mechanisms of Prostate Cancer with Small Molecules that Target Androgen Receptor–Chromatin Interactions
2023Open Access
Supplementary Figure 6 from Characterization of a New Class of Androgen Receptor Antagonists with Potential Therapeutic Application in Advanced Prostate Cancer
2023Open Access
Supplementary Figure 2 from Characterization of a New Class of Androgen Receptor Antagonists with Potential Therapeutic Application in Advanced Prostate Cancer
2023Open Access
Data from Characterization of a New Class of Androgen Receptor Antagonists with Potential Therapeutic Application in Advanced Prostate Cancer
2023Open Access
Supplementary Figure 3 from Characterization of a New Class of Androgen Receptor Antagonists with Potential Therapeutic Application in Advanced Prostate Cancer
2023Open Access
Supplementary Figure 5 from Characterization of a New Class of Androgen Receptor Antagonists with Potential Therapeutic Application in Advanced Prostate Cancer
2023Open Access
Supplementary Figure 3 from Characterization of a New Class of Androgen Receptor Antagonists with Potential Therapeutic Application in Advanced Prostate Cancer
2023Open Access
Supplementary Figure 6 from Characterization of a New Class of Androgen Receptor Antagonists with Potential Therapeutic Application in Advanced Prostate Cancer
2023Open Access
Supplementary Figure 5 from Characterization of a New Class of Androgen Receptor Antagonists with Potential Therapeutic Application in Advanced Prostate Cancer
2023Open Access
Supplementary Materials and Methods from Characterization of a New Class of Androgen Receptor Antagonists with Potential Therapeutic Application in Advanced Prostate Cancer
2023Open Access
Table S1 and Figure S1-S4 from Bypassing Drug Resistance Mechanisms of Prostate Cancer with Small Molecules that Target Androgen Receptor–Chromatin Interactions
2023Open Access
Data from Characterization of a New Class of Androgen Receptor Antagonists with Potential Therapeutic Application in Advanced Prostate Cancer
2023Open Access
Data from Bypassing Drug Resistance Mechanisms of Prostate Cancer with Small Molecules that Target Androgen Receptor–Chromatin Interactions
2023Open Access
page 1 of 4Next →

Frequent Co-authors

Artem Cherkasov(48), Paul S. Rennie(44), Fuqiang Ban(29), Kriti Singh(23), Nada Lallous(19), Nathan A. Lack(15), Emma Tomlinson Guns(15), Kate Frewin(15), Mohamed D.H. Hassona(15), Huifang Li(14), Hélène Morin(14), Kush Dalal(13), Peter Axerio-Cilies(12), Hans Adomat(12), Martin Gleave(10), Peyman Tavassoli(10), Helge Prinz(10), Mani Roshan‐Moniri(9), Huifang Li(9), Natalia Kanaan(9)